We empower our researchers to turn their most promising discoveries into commercially viable assets. Trainees also receive the guidance needed to launch new companies.


(so far)


by Alumni



As an academic research organization within the University of Washington School of Medicine, the Institute for Protein Design conducts translational research to ensure our innovations benefit the world. We’re proud to have seeded multiple biotech companies, especially in the Pacific Northwest region. However, as a non-commercial entity, the Institute receives minimal or no direct benefit from these commercial activities. Instead, we remain primarily funded through grants and philanthropic donations. We are grateful to all who generously support our mission.


Cyrus Biotechnology


Cyrus aims to use Rosetta, AI algorithms, and massively parallel cell-based screening to create unique therapeutics. The company has also created an online GUI that brings the core suite of Rosetta algorithms to over 100 life science companies. —

PvP Biologics


PvP was founded to ease the burden of living with celiac disease. Acquired by Takeda Pharmaceuticals in 2020, the company developed an enzyme to break down gluten in the stomach that is in human clinical testing today. —

Icosavax, Inc


Icosavax was founded to develop safe and effective vaccines for a variety of infectious diseases. It was acquired by AstraZeneca in 2024. —

A-Alpha Bio


A-Alpha is advancing technology to aid in the development of drugs that interact with multiple targets. This includes is a multiplexed quantitative platform for characterizing entire protein interaction networks in a single test tube. —

Neoleukin Therapeutics


Neoleukin was formed to advance proteins for cancer immunotherapy. It merged with New York-based Neurogene in 2023. —

Mopac Biologics, Inc.


Mopac seeks to create safe, effective, and convenient therapies for autoinflammatory disease. The company’s lead molecule, MB1, is an oral protein inhibitor of IL-23R in preclinical development for the treatment of inflammatory bowel disease.

Monod Bio, Inc.


Monod is developing advanced biosensors. Their technology combines binding, transduction, and amplification to detect a wide range of target molecules, enabling the development of simple, powerful sensors for biotechnology and medicine. —

Lila Biologics, Inc.


Lila aims to design highly selective integrin inhibitor therapeutics for diseases including idiopathic pulmonary fibrosis, a debilitating lung condition that affects millions worldwide.

Vilya, Inc.


Vilya is using advanced computational design approaches to amass vast libraries of membrane-permeable peptides for drug development. —

Archon Biosciences, Inc.


Archon is advancing regenerative medicine and cancer therapy by developing treatments that combine off-the-shelf antibodies with de novo designed nanoparticles.